

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)



(10) International Publication Number
WO 2022/100748 A1

(51) International Patent Classification:

C12N 15/35 (2006.01) A61K 48/00 (2006.01)
C07K 14/015 (2006.01) A61P 11/00 (2006.01)
C12N 15/864 (2006.01)

(21) International Application Number:

PCT/CN2021/130784

(22) International Filing Date:

16 November 2021 (16.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/129001

16 November 2020 (16.11.2020) CN

(71) Applicants: **STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.** [CN/CN]; No. 36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). **BEIJING SOLOBO GENETECHNOLOGY COMPANY LTD.** [CN/CN]; Room 401, Building 5, No. 36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN).

(72) Inventors: **ZHANG, Tingting**; No. 36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN). **WANG, Chao**; No. 36, Jinghai Er Road, Beijing Economic-Technological Development Area, Beijing 100176 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: RECOMBINANT ADENO-ASSOCIATED VIRUSES WITH ENHANCED LIVER TROPISM AND USES THEREOF




Fig. 14B

(57) Abstract: Recombinant adenovirus-associated viruses are described. The recombinant adenovirus-associated viruses may comprise a capsid protein with enhanced tropism for liver cells. The recombinant adenovirus-associated viruses may also exhibit less immunogenicity in humans. The recombinant adenovirus-associated viruses may comprise expression cassettes comprising a polynucleotide sequence encoding a therapeutic agent useful in gene therapy treatment of a liver disease. Preparation systems for packaging the recombinant adenovirus-associated viruses, methods of producing the recombinant adenovirus-associated viruses, pharmaceutical compositions comprising the recombinant adenovirus-associated viruses, and uses of said compositions for treating liver diseases including Fabry disease and Hepatitis B, are also provided.

WO 2022/100748 A1